Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability

Overview

Journal Theranostics

Date 2011 Aug 19

PMID 21850213

Citations 25

Authors

Jiyun Shi

Yang Zhou

Sudipta Chakraborty

Young-Seung Kim

Bing Jia

Fan Wang

Shuang Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to demonstrate the valence of cyclic RGD peptides, P-RGD (PEG(4)-c(RGDfK): PEG(4) = 15-amino-4,710,13-tetraoxapentadecanoic acid), P-RGD(2) (PEG(4)-E[c(RGDfK)](2), 2P-RGD(4) (E{PEG(4)-E[c(RGDfK)](2)}(2), 2P4G-RGD(4) (E{PEG(4)-E[G(3)-c(RGDfK)](2)}(2): G(3) = Gly-Gly-Gly) and 6P-RGD(4) (E{PEG(4)-E[PEG(4)-c(RGDfK)](2)}(2)) in binding to integrin α(v)β(3), and to assess the impact of peptide and linker multiplicity on biodistribution properties, excretion kinetics and metabolic stability of their corresponding (111)In radiotracers.

Methods: Five new RGD peptide conjugates (DOTA-P-RGD (DOTA =1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid), DOTA-P-RGD(2), DOTA-2P-RGD(4), DOTA-2P4G-RGD(4), DOTA-6P-RGD(4)), and their (111)In complexes were prepared. The integrin α(v)β(3) binding affinity of cyclic RGD conjugates were determined by a competitive displacement assay against (125)I-c(RGDyK) bound to U87MG human glioma cells. Biodistribution, planar imaging and metabolism studies were performed in athymic nude mice bearing U87MG human glioma xenografts.

Results: The integrin α(v)β(3) binding affinity of RGD conjugates follows the order of: DOTA-6P-RGD(4) (IC(50) = 0.3 ± 0.1 nM) ~ DOTA-2P4G-RGD(4) (IC(50) = 0.2 ± 0.1 nM) ~ DOTA-2P-RGD(4) (IC(50) = 0.5 ± 0.1 nM) > DOTA-3P-RGD(2) (DOTA-PEG(4)-E[PEG(4)-c(RGDfK)](2): IC(50) = 1.5 ± 0.2 nM) > DOTA-P-RGD(2) (IC(50) = 5.0 ± 1.0 nM) >> DOTA-P-RGD (IC(50) = 44.3 ± 3.5 nM) ~ c(RGDfK) (IC(50) = 49.9 ± 5.5 nM) >> DOTA-6P-RGK(4) (IC(50) = 437 ± 35 nM). The fact that DOTA-6P-RGK(4) had much lower integrin α(v)β(3) binding affinity than DOTA-6P-RGD(4) suggests that the binding of DOTA-6P-RGD(4) to integrin α(v)β(3) is RGD-specific. This conclusion is consistent with the lower tumor uptake for (111)In(DOTA-6P-RGK(4)) than that for (111)In(DOTA-6P-RGD(4)). It was also found that the G(3) and PEG(4) linkers between RGD motifs have a significant impact on the integrin α(v)β(3)-targeting capability, biodistribution characteristics, excretion kinetics and metabolic stability of (111)In-labeled cyclic RGD peptides.

Conclusion: On the basis of their integrin α(v)β(3) binding affinity and tumor uptake of their corresponding (111)In radiotracers, it was conclude that 2P-RGD(4), 2P4G-RGD(4) and 6P-RGD(4) are most likely bivalent in binding to integrin α(v)β(3), and extra RGD motifs might contribute to the long tumor retention times of (111)In(DOTA-2P-RGD(4)),( 111)In(DOTA-2P4G-RGD(4)) and (111)In(DOTA-6P-RGD(4)) than that of (111)In(DOTA-3P-RGD(3)) at 72 h p.i. Among the (111)In-labeled cyclic RGD tetramers evaluated in the glioma model, (111)In(DOTA-2P4G-RGD(4)) has very high tumor uptake with the best tumor/kidney and tumor/liver ratios, suggesting that (90)Y(DOTA-2P4G-RGD(4)) and (177)Lu(DOTA-2P4G-RGD(4)) might have the potential for targeted radiotherapy of integrin α(v)β(3)-positive tumors.

Citing Articles

Current trends in the characterization and monitoring of vascular response to cancer therapy.

Shrestha B, Stern N, Zhou A, Dunn A, Porter T Cancer Imaging. 2024; 24(1):143.

PMID: 39438891 PMC: 11515715. DOI: 10.1186/s40644-024-00767-8.

Antimicrobial peptides CS-piscidin-induced cell death involves activation of RIPK1/PARP, and modification with myristic acid enhances its stability and tumor-targeting capability.

Li N, Jiang X, Ma X, Qiu X, Chang H, Qiao Y Discov Oncol. 2023; 14(1):38.

PMID: 37000327 PMC: 10066050. DOI: 10.1007/s12672-023-00642-1.

Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer Tc-HP-Ark2: a pilot study.

Shi J, Du S, Wang R, Gao H, Luo Q, Hou G J Transl Med. 2023; 21(1):19.

PMID: 36631812 PMC: 9835228. DOI: 10.1186/s12967-022-03865-y.

Palmitic Acid-Conjugated Radiopharmaceutical for Integrin αβ-Targeted Radionuclide Therapy.

Yang G, Gao H, Luo C, Zhao X, Luo Q, Shi J Pharmaceutics. 2022; 14(7).

PMID: 35890224 PMC: 9321335. DOI: 10.3390/pharmaceutics14071327.

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice.

Lo W, Lo S, Chen S, Chen M, Huang Y, Chen L Int J Mol Sci. 2021; 22(11).

PMID: 34064291 PMC: 8196871. DOI: 10.3390/ijms22115459.

References

Shi J, Kim Y, Chakraborty S, Jia B, Wang F, Liu S . 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem. 2009; 20(8):1559-68. PMC: 2888811. DOI: 10.1021/bc9001739. View

Liu S, He Z, Hsieh W, Kim Y, Jiang Y . Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. Bioconjug Chem. 2006; 17(6):1499-507. PMC: 2562319. DOI: 10.1021/bc060235l. View

Liu S, Edwards D, Ziegler M, Harris A, Hemingway S, Barrett J . 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem. 2001; 12(4):624-9. DOI: 10.1021/bc010012p. View

Janssen M, Oyen W, Massuger L, Frielink C, Dijkgraaf I, Edwards D . Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2003; 17(6):641-6. DOI: 10.1089/108497802320970244. View

Janssen M, Oyen W, Dijkgraaf I, Massuger L, Frielink C, Edwards D . Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002; 62(21):6146-51. View

Dijkgraaf I, Yim C, Franssen G, Schuit R, Luurtsema G, Liu S . PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging. 2010; 38(1):128-37. PMC: 3005123. DOI: 10.1007/s00259-010-1615-x. View

Dijkgraaf I, Kruijtzer J, Liu S, Soede A, Oyen W, Corstens F . Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2006; 34(2):267-73. DOI: 10.1007/s00259-006-0180-9. View

Chen X . Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem. 2006; 6(2):227-34. DOI: 10.2174/138955706775475975. View

Shi J, Wang L, Kim Y, Zhai S, Liu Z, Chen X . Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008; 51(24):7980-90. PMC: 2626178. DOI: 10.1021/jm801134k. View

10.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher D, Liu S . microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005; 46(10):1707-18. View

11.

Dijkgraaf I, Liu S, Kruijtzer J, Soede A, Oyen W, Liskamp R . Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl Med Biol. 2007; 34(1):29-35. DOI: 10.1016/j.nucmedbio.2006.10.006. View

12.

Wu Z, Li Z, Chen K, Cai W, He L, Chin F . microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med. 2007; 48(9):1536-44. PMC: 4183663. DOI: 10.2967/jnumed.107.040816. View

13.

Liu S . Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem. 2009; 20(12):2199-213. PMC: 2795072. DOI: 10.1021/bc900167c. View

14.

Thumshirn G, Hersel U, Goodman S, Kessler H . Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry. 2003; 9(12):2717-25. DOI: 10.1002/chem.200204304. View

15.

Liu Z, Wang F, Chen X . Integrin targeted delivery of radiotherapeutics. Theranostics. 2011; 1:201-10. PMC: 3086619. DOI: 10.7150/thno/v01p0201. View

16.

Zhang X, Xiong Z, Wu Y, Cai W, Tseng J, Gambhir S . Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med. 2006; 47(1):113-21. PMC: 4160026. View

17.

Haubner R, Wester H . Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004; 10(13):1439-55. DOI: 10.2174/1381612043384745. View

18.

Cai W, Rao J, Gambhir S, Chen X . How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006; 5(11):2624-33. DOI: 10.1158/1535-7163.MCT-06-0395. View

19.

Liu S . Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm. 2006; 3(5):472-87. DOI: 10.1021/mp060049x. View

20.

Shi J, Kim Y, Zhai S, Liu Z, Chen X, Liu S . Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem. 2009; 20(4):750-9. PMC: 2676896. DOI: 10.1021/bc800455p. View